CA3088339A1 - Periodontitis diagnostic methods, uses and kits - Google Patents
Periodontitis diagnostic methods, uses and kits Download PDFInfo
- Publication number
- CA3088339A1 CA3088339A1 CA3088339A CA3088339A CA3088339A1 CA 3088339 A1 CA3088339 A1 CA 3088339A1 CA 3088339 A CA3088339 A CA 3088339A CA 3088339 A CA3088339 A CA 3088339A CA 3088339 A1 CA3088339 A1 CA 3088339A1
- Authority
- CA
- Canada
- Prior art keywords
- periodontitis
- light chain
- protein
- free light
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001245 periodontitis Diseases 0.000 title claims abstract description 115
- 238000002405 diagnostic procedure Methods 0.000 title description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 142
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 140
- 239000000090 biomarker Substances 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 56
- 210000003296 saliva Anatomy 0.000 claims abstract description 48
- 238000012360 testing method Methods 0.000 claims abstract description 31
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 39
- 238000001514 detection method Methods 0.000 claims description 39
- 238000009739 binding Methods 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 52
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 208000028169 periodontal disease Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000007565 gingivitis Diseases 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 201000005562 gingival recession Diseases 0.000 description 4
- 230000003239 periodontal effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 208000008312 Tooth Loss Diseases 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 101100239712 Caenorhabditis elegans unc-15 gene Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- -1 biomarker proteins Chemical class 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005315 distribution function Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 101710172804 K protein Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 208000009596 Tooth Mobility Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 201000011560 gingival overgrowth Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001036 tooth cervix Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/18—Dental and oral disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18151839.0 | 2018-01-16 | ||
| EP18151839.0A EP3511716A1 (en) | 2018-01-16 | 2018-01-16 | Periodontitis diagnostic methods, uses and kits |
| PCT/EP2019/050364 WO2019141547A1 (en) | 2018-01-16 | 2019-01-09 | Periodontitis diagnostic methods, uses and kits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3088339A1 true CA3088339A1 (en) | 2019-07-25 |
Family
ID=61131917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3088339A Pending CA3088339A1 (en) | 2018-01-16 | 2019-01-09 | Periodontitis diagnostic methods, uses and kits |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210063412A1 (enExample) |
| EP (2) | EP3511716A1 (enExample) |
| JP (2) | JP7330983B2 (enExample) |
| CN (1) | CN111630389B (enExample) |
| CA (1) | CA3088339A1 (enExample) |
| RU (1) | RU2020127365A (enExample) |
| WO (1) | WO2019141547A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3553523A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Diagnostics of mild or advanced periodontitis |
| EP3553520A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Methods, uses and kits for monitoring or predicting response to periodontal disease treatment |
| WO2022096893A1 (en) | 2020-11-04 | 2022-05-12 | The University Of Birmingham | Device |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179606B2 (en) * | 2001-11-23 | 2007-02-20 | Syn X Pharma, Inc. | IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease |
| CN101523218B (zh) * | 2006-09-29 | 2014-07-09 | 霍夫曼-拉罗奇有限公司 | 评估类风湿性关节炎患者疾病进展的风险 |
| US8728744B2 (en) * | 2007-10-26 | 2014-05-20 | The Regents Of The University Of California | Salivary protein biomarkers for human oral cancer |
| CN105866423A (zh) * | 2009-05-14 | 2016-08-17 | 牛津大学之校长及学者 | 使用一组新型低丰度人类血浆蛋白生物标记对肝纤维化进行临床诊断 |
| US10132811B2 (en) * | 2009-06-25 | 2018-11-20 | The Regents Of The University Of California | Salivary transcriptomic and microbial biomarkers for pancreatic cancer |
| WO2011133770A2 (en) * | 2010-04-21 | 2011-10-27 | Board Of Regents Of The University Of Texas System | Salivary protein markers for detection of breast cancer |
| JP5869323B2 (ja) * | 2011-12-01 | 2016-02-24 | 花王株式会社 | 歯周病マーカー |
| RU2015113089A (ru) * | 2012-09-10 | 2016-10-27 | Конинклейке Филипс Н.В. | Анализ протеома слюны на биомаркеры гингивита и периодонтита с использованием ft-icr-ms/ms |
| WO2015087985A1 (ja) * | 2013-12-11 | 2015-06-18 | 株式会社資生堂 | 腎不全の早期診断マーカー |
| ES2870983T3 (es) * | 2014-12-19 | 2021-10-28 | Univ Nantes | Anticuerpos anti-IL-34 |
| GB201708262D0 (en) * | 2017-05-23 | 2017-07-05 | Binding Site Group Ltd | Assay for plasma cell associated disease |
-
2018
- 2018-01-16 EP EP18151839.0A patent/EP3511716A1/en not_active Withdrawn
-
2019
- 2019-01-09 CA CA3088339A patent/CA3088339A1/en active Pending
- 2019-01-09 EP EP19700162.1A patent/EP3740759B1/en active Active
- 2019-01-09 RU RU2020127365A patent/RU2020127365A/ru unknown
- 2019-01-09 CN CN201980008597.5A patent/CN111630389B/zh active Active
- 2019-01-09 WO PCT/EP2019/050364 patent/WO2019141547A1/en not_active Ceased
- 2019-01-09 US US16/962,249 patent/US20210063412A1/en not_active Abandoned
- 2019-01-09 JP JP2020538662A patent/JP7330983B2/ja active Active
-
2023
- 2023-07-05 JP JP2023110445A patent/JP2023134563A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7330983B2 (ja) | 2023-08-22 |
| JP2023134563A (ja) | 2023-09-27 |
| JP2021510815A (ja) | 2021-04-30 |
| EP3740759A1 (en) | 2020-11-25 |
| EP3740759C0 (en) | 2025-04-30 |
| CN111630389A (zh) | 2020-09-04 |
| EP3740759B1 (en) | 2025-04-30 |
| WO2019141547A1 (en) | 2019-07-25 |
| US20210063412A1 (en) | 2021-03-04 |
| RU2020127365A3 (enExample) | 2022-04-08 |
| RU2020127365A (ru) | 2022-02-17 |
| EP3511716A1 (en) | 2019-07-17 |
| CN111630389B (zh) | 2025-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7330195B2 (ja) | 歯周疾患診断法、用途、キット | |
| US12050223B2 (en) | Diagnostics of mild or advanced periodontitis based on salivary IL-1BETA and MMP-9 | |
| EP3740759B1 (en) | Periodontitis diagnostic methods, uses and kits | |
| CA3096499A1 (en) | Diagnostics of mild or advanced periodontitis | |
| US20230393149A1 (en) | Diagnostics of gingivitis | |
| EP3775920B1 (en) | Gingivitis diagnostic methods, uses and kits | |
| JP7454503B2 (ja) | 軽度又は進行性の歯周病の診断 | |
| US20250020664A1 (en) | Diagnostics of mild or advanced periodontitis based on salivary il-1beta and mmp-9 | |
| EP3407068A1 (en) | Diagnostics of mild or advanced periodontitis based on salivary il-1beta and mmp-9 | |
| US20210164996A1 (en) | Periodontitis diagnostic methods, uses and kits | |
| US20210132083A1 (en) | Methods, uses and kits for monitoring or predicting response to periodontal disease treatment | |
| EP3407069A1 (en) | Diagnostics of gingivitis based on salivary il-1beta and hgf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231205 |
|
| EEER | Examination request |
Effective date: 20231205 |